Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CDX-1140 + CDX-301|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CDX-1140||CDX-1140 is an antibody that binds CD40 and activates signaling, potentially resulting in enhanced anti-tumor immune response (Blood, 128(22), 1848).|
|CDX-301||Mobista||Mobista (CDX-301) is a recombinant Flt3 ligand that binds to and activates the Flt3 receptor, leading to proliferation of immune precursor cells (PMID: 25915810).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||CDX-1140 + CDX-301||Phase I||Emerging||In a Phase I trial, CDX-1140 and CDX-301 combination treatment demonstrated safety and expected lymphocyte activation and cytokine responses in patients with advanced solid tumors (AACR Annual Meeting 2019, Abstract LB_194; NCT03329950).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03329950||Phase I||CDX-1140 + CDX-301 CDX-1140||A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors||Recruiting|